search
Back to results

GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance (GERABEL)

Primary Purpose

Breast Cancer

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Onco Geriatric Evaluation
Sponsored by
Centre Hospitalier Universitaire de Saint Etienne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Breast Cancer focused on measuring Breast Cancer, Onco Geriatric Evaluation, Radiotherapy, Hypo fractionated radiotherapy, Normo fractionated radiotherapy, Large hypo fractionated radiotherapy

Eligibility Criteria

70 Years - undefined (Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Woman more than 70 years old,
  • Patient carrying a breast cancer proven histologically and treated by radiotherapy in curative intent.

Exclusion Criteria:

  • Man,
  • Patient with metastatic cancer,
  • Patient with impossible follow-up at 6 months (planned relocation, patient support in another Center),
  • Patient under protection of justice or unable to give consent.

Sites / Locations

  • Centre Hospitalier Emile Roux
  • Groupement Hospitalier Portes de Provence
  • Institut de Cancérologie Lucien Neuwirth

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Score of the Onco Geriatric Evaluation between 200 et 160

Score of the Onco Geriatric Evaluation between 159 et 120

Score of the Onco Geriatric Evaluation inferior to 119

Arm Description

According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.

According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.

According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.

Outcomes

Primary Outcome Measures

Measure of the tolerance
Tolerance is considered as " bad " if the score of the onco geriatric evaluation decreases of more than 20% from the initial evaluation to 6 months after the end of the rays. Tolerance is considered as "correct" in the other cases.

Secondary Outcome Measures

Tolerance
Specific tolerance will be evaluated by the number of radiation-induced toxicities (Common Terminology Criteria for Adverse Events 4.4) of I, II, III, and IV grades.
Quality of Life Questionnaire
Quality of life will be assessed with the difference between the Quality of Life Questionnaire 30 of the European Organisation for Research and Treatment of Cancer (EORTC) score obtained before the radiotherapy and 6 months after the end of the radiation therapy.
Radiotherapy compliance
Compliance is considered as "bad" if the treatment plan is interrupted for at least one day (for medical reason). Compliance is considered as "correct" in the other cases.
Correlation between tolerance and distance from the therapeutic center
Correlation will potentially be established between patient general tolerance and the distance between home and radio therapeutic center.
Correlation between tolerance and way of transport
Correlation will potentially be established between patient general tolerance and the way of transport used by the patient to go to the therapeutic center.
Correlation between tolerance and the number of concomitant treatments
Correlation will potentially be established between patient general tolerance and the number of concomitant treatments.
Correlation between tolerance and the nature of concomitant treatments
Correlation will potentially be established between patient general tolerance and the nature of concomitant treatments.
Correlation between tolerance and the supportive cares
Correlation will potentially be established between patient general tolerance and the supportive cares performed.

Full Information

First Posted
September 21, 2016
Last Updated
February 4, 2022
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Centre Antoine Lacassagne, Institut de Cancérologie de la Loire
search

1. Study Identification

Unique Protocol Identification Number
NCT02994914
Brief Title
GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance
Acronym
GERABEL
Official Title
GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance : GERABEL Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Terminated
Why Stopped
Low rythm of inclusions
Study Start Date
December 5, 2016 (Actual)
Primary Completion Date
June 26, 2020 (Actual)
Study Completion Date
June 26, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Centre Antoine Lacassagne, Institut de Cancérologie de la Loire

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study proposes an onco geriatric evaluation (Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and " timed get up and go " tests) for elderly breast cancer patients. The score obtained at this evaluation will determine the radiotherapy scheme.
Detailed Description
Breast cancer is the most frequent cancer for elderly women and represents the first mortality cause for them. Breast cancer incidence increases for elderly women and will become a major public health problem in the next years. The principal therapeutic solution is the partial mastectomy associated to radiotherapy. However, the radiotherapy scheme and its role are debated for elderly patients. Hypo fractionated radiotherapy could be considered as an advantageous option. The treatment duration (6,5 weeks) and direct and indirect fatigue (around 33 travels) are major cons. Thereby, for elderly patients, the selection of patients who will benefit from a shorter treatment could be really difficult. It would be interesting to define an objective scoring, predicting a bad or good tolerance and observance to the radiotherapy. Nowadays, onco geriatric evaluations are used to decide some treatment's decision, but no study compared different orientated radiotherapy schemes. The present study proposes an onco geriatric evaluation leading to a score according to seven tests (Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and " timed get up and go " tests). The score will then determine an adapted radiotherapy scheme.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast Cancer, Onco Geriatric Evaluation, Radiotherapy, Hypo fractionated radiotherapy, Normo fractionated radiotherapy, Large hypo fractionated radiotherapy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
241 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Score of the Onco Geriatric Evaluation between 200 et 160
Arm Type
Experimental
Arm Description
According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
Arm Title
Score of the Onco Geriatric Evaluation between 159 et 120
Arm Type
Experimental
Arm Description
According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
Arm Title
Score of the Onco Geriatric Evaluation inferior to 119
Arm Type
Experimental
Arm Description
According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
Intervention Type
Other
Intervention Name(s)
Onco Geriatric Evaluation
Intervention Description
Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and " timed get up and go " tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy.
Primary Outcome Measure Information:
Title
Measure of the tolerance
Description
Tolerance is considered as " bad " if the score of the onco geriatric evaluation decreases of more than 20% from the initial evaluation to 6 months after the end of the rays. Tolerance is considered as "correct" in the other cases.
Time Frame
Month 6
Secondary Outcome Measure Information:
Title
Tolerance
Description
Specific tolerance will be evaluated by the number of radiation-induced toxicities (Common Terminology Criteria for Adverse Events 4.4) of I, II, III, and IV grades.
Time Frame
Month 6
Title
Quality of Life Questionnaire
Description
Quality of life will be assessed with the difference between the Quality of Life Questionnaire 30 of the European Organisation for Research and Treatment of Cancer (EORTC) score obtained before the radiotherapy and 6 months after the end of the radiation therapy.
Time Frame
Month 6
Title
Radiotherapy compliance
Description
Compliance is considered as "bad" if the treatment plan is interrupted for at least one day (for medical reason). Compliance is considered as "correct" in the other cases.
Time Frame
Month 6
Title
Correlation between tolerance and distance from the therapeutic center
Description
Correlation will potentially be established between patient general tolerance and the distance between home and radio therapeutic center.
Time Frame
Month 6
Title
Correlation between tolerance and way of transport
Description
Correlation will potentially be established between patient general tolerance and the way of transport used by the patient to go to the therapeutic center.
Time Frame
Month 6
Title
Correlation between tolerance and the number of concomitant treatments
Description
Correlation will potentially be established between patient general tolerance and the number of concomitant treatments.
Time Frame
Month 6
Title
Correlation between tolerance and the nature of concomitant treatments
Description
Correlation will potentially be established between patient general tolerance and the nature of concomitant treatments.
Time Frame
Month 6
Title
Correlation between tolerance and the supportive cares
Description
Correlation will potentially be established between patient general tolerance and the supportive cares performed.
Time Frame
Month 6

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Woman more than 70 years old, Patient carrying a breast cancer proven histologically and treated by radiotherapy in curative intent. Exclusion Criteria: Man, Patient with metastatic cancer, Patient with impossible follow-up at 6 months (planned relocation, patient support in another Center), Patient under protection of justice or unable to give consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolas Magné, PhD
Organizational Affiliation
Institut de Cancérologie Lucien Neuwirth
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Emile Roux
City
Le Puy-en-Velay
ZIP/Postal Code
43000
Country
France
Facility Name
Groupement Hospitalier Portes de Provence
City
Montelimar
ZIP/Postal Code
26216
Country
France
Facility Name
Institut de Cancérologie Lucien Neuwirth
City
Saint-Priest en Jarez
ZIP/Postal Code
42270
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance

We'll reach out to this number within 24 hrs